Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4 , Pages 363-366 , July 2009

P-glycoprotein activity in renal clear cell carcinoma

  • Elena Soto-Vega, Ph.D.

      Affiliations

    • Unit of Research of Autoimmune Diseases, Instituto Mexicano del Seguro Social, Puebla, Mexico
    • These authors collaborated equally to this work.
    • ,
  • Carlos Arroyo, M.D., Ph.D.

      Affiliations

    • Department of Surgery, Hospital Universitario de Puebla, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
    • These authors collaborated equally to this work.
    • ,
  • Yvonne Richaud-Patin, B.S.

      Affiliations

    • Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico DF, Mexico
    • ,
  • Mario García-Carrasco, M.D.

      Affiliations

    • Unit of Research of Autoimmune Diseases, Instituto Mexicano del Seguro Social, Puebla, Mexico
    • ,
  • Luis G. Vázquez-Lavista, M.D.

      Affiliations

    • Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico DF, Mexico
    • ,
  • Luis Llorente, M.D.

      Affiliations

    • Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico DF, Mexico
    • Corresponding Author InformationCorresponding author. Tel.: +(52) 55 56 55-5954; fax: +(52) 55 5517-2096

Received 22 November 2007 ,Revised 24 January 2008 ,Accepted 25 January 2008.

References 

  1. Jemal A, Murray T, Ward E. Cancer statistics. CA Cancer J Clin. 2005;55:10–30
  2. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet. 1998;352:1691–1696
  3. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last two decades in the United States: An analysis of surveillance, epidemiology and end results program data. J Urol. 2002;167:57–60
  4. Ramsey S, Aitchinson M. Treatment for renal cell: Are we beyond the cytokine era?. Nat Clin Pract Urol. 2006;3:478–484
  5. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  7. Inui K, Masuda S, Satio H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 2000;58:944–958
  8. Chang G. Multidrug resistance ABC transporters. FEBS Lett. 2003;27:102–105
  9. Liang XJ, Aszalos A. Multidrug transporters as drug targets. Curr Drug Targets. 2006;7:911–921
  10. Tsuruo T. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep. 1983;67:889–894
  11. Ueda K, Cardarelli C, Gottesman MM, et al. Expression of a full length cDNA from the human MDR-1 gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 1987;84:3004–3008
  12. Juranka PF, Zastawny RL, Ling V. P-glycoprotein: Multidrug resistance and a superfamily of membrane-associated transport proteins. FASEB J. 1989;324:485–489
  13. Bradley G, Naik M, Ling V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res. 1989;49:2790–2796
  14. Hill BT, Deuchars K, Hosking LK. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractioned X irradiation in vitro. J Natl Cancer Inst. 1990;82:607–612
  15. McClean S, Hill BT. Evidence of post-translational regulation of P-glycoprotein associated with expression of a distinctive multiple drug-resistant phenotype in Chinese hamster ovary cells. Eur J Cancer. 1993;29A:2243–2248
  16. Cornwell MM, Pastan I, Gottesman MM. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane besides and inhibit drug binding to P-glycoprotein. J Biol Chem. 1987;262:2166–2170
  17. Safa AR. Photoaffinity labeling of the multidrug resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci. 1998;85:7187–7191
  18. Safa AR, Glover CJ, Sewell JL, et al. Identification of the multidrug resistance-related membrane glycoprotein as acceptor for calcium channel blockers. J Biol Chem. 1987;262:7884–7888
  19. McCoy JP, Keren DF. Current practices in clinical flow cytometry (A practice survey by the American Society of clinical pathologist). Am J Pathol. 1999;111:161–168
  20. Mathew A, Devesa SS, Fraumeni JF, et al. Global increases in kidney cancer incidence, 1973–1992. Eur J Cancer Prev. 2002;11:171–178
  21. Nguyen MM, Gill IS, Ellison LM. The evolving presentation of renal carcinoma in the United States: Trends from the surveillance, epidemiology and end results program. J Urol. 2006;176:2397–2400
  22. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006;176:2353–2358
  23. Fojo T. Multiple paths to a drug resistance phenotype mutations, translocations, deletions and amplifications of coding genes or promoter regions, epigenetic changes and micro RNAs. Drug Resist Update. 2007;10:59–67
  24. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature. 2007;446:749–757
  25. Huff LM, Lee JS, Robey RW, et al. Characterization of gene rearrangements leading to activation of MDR-1. J Biol Chem. 2006;281:36501–36509
  26. Harada T, Nagayama J, Kohno K, et al. Alu-associated interstitial deletions and chromosomal rearrangements in two human multidrug-resistant cell lines. Int J Cancer. 2000;86:506–511
  27. Asakura T, Imai A, Ohkubo-Uraoka N, et al. Relationship between expression of drug-resistance factors and drug sensitivity in normal human renal proximal tubular epithelial cells in comparison with renal cell carcinoma. Oncol Rep. 2005;14:601–607
  28. Mignogna C, Staibano S, Altieri V, et al. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: A five-year follow-up analysis. BMC Cancer. 2006;6:293–303
  29. Aouali N, Eddabra L, Macadré J, et al. Immunosuppressors and reversion of multidrug-resistance. Crit Rev Oncol Hematol. 2005;56:61–70
  30. Bates SE. Solving the problems of multidrug resistance: ABC transporters in clinical oncology. In:  Holland IB,  Cole SP,  Kuchler K, et al. editor. ABC proteins: From bacteria to man. London: Elsevier Science; 2002;p. 670–678

PII: S1078-1439(08)00013-6

doi: 10.1016/j.urolonc.2008.01.011

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4 , Pages 363-366 , July 2009

Article Tools

* Image Usage & Resolution